Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mod GRF 1-29

Sermorelin, Growth Hormone Releasing Hormone (1-29), hGRF(1-29)NH2

Quick Stats
Studies 227
Trials 47
Score 2
2002 pubmed 32 citations

Transcriptional and post-transcriptional regulation of tyrosine hydroxylase messenger RNA in PC12 cells during persistent stimulation by VIP and PACAP38: differential regulation by protein kinase A and protein kinase C-dependent pathways.

Corbitt. J J; Hagerty. T T; Fernandez. E E; Morgan. W W WW; Strong. R R

Key Findings

  • PACAP38 is more potent and effective than VIP at increasing TH mRNA levels.
  • PACAP38 produces a sustained, post‑transcriptional rise in TH mRNA that lasts up to 2 days, linked to PKC activation.

Practical Outcomes

  • The study hints that PACAP38 could theoretically boost catecholamine (dopamine, norepinephrine) synthesis, which might affect energy, mood, or performance. However, because the work is limited to rat cell lines and no human dosing or safety data exist, it does not yet support any concrete supplementation or protocol for biohackers.

Summary

In a cell‑culture study, the peptide PACAP38 was shown to raise the messenger RNA for tyrosine hydroxylase (the enzyme that starts dopamine and norepinephrine production) more strongly and for a longer time than the related peptide VIP. This effect depends on activating a protein‑kinase C (PKC) pathway, while VIP does not trigger PKC. The findings come from rat PC12 cells, not humans, so they are not directly actionable for personal use.

Abstract

VIP and PACAP38 are closely related peptides that are released in the adrenal gland and sympathetic ganglia and regulate catecholamine synthesis and release. We used PC12 cells as a model system to examine receptor and second messenger pathways by which each peptide stimulates transcriptional and post-transcriptional mechanisms that regulate the level of the mRNA for tyrosine hydroxylase (TH), the rate-limiting enzymatic step in catecholamine synthesis. Concentration-response studies revealed that PACAP38 had both greater efficacy and potency than VIP. The specific PAC1 receptor antagonist PACAP[6-38] blocked the effects of each peptide on TH mRNA content while the PACAP/VIP type II receptor antagonist (N-AC-Tyr(1)-D-Phe(2))-GRF-(1-29)-NH(2) was without effect. At equipotent concentrations, each peptide stimulated a transient increase in TH gene transcription lasting less than 3h. Continuous VIP treatment stimulated a transient increase in TH mRNA lasting less than 24h. In contrast, continuous exposure to PACAP38 stimulated a stable increase in TH mRNA that persisted for 2 days in the absence of elevated transcription, pointing to different post-transcriptional effects of the two peptides. PACAP38 alone had no effect on the magnitude of TH gene transcription or TH mRNA in A126-1B2 PKA-deficient PC12 cells. However, when combined with dexamethasone, PACAP38 produced a synergistic increase in TH mRNA in the absence of PACAP38-stimulated TH gene transcription. In contrast, VIP had no effect on either TH mRNA content or TH gene transcription in this model. PACAP38, but not VIP, stimulated PKC activity. Calphostin C antagonized the effect of PACAP38 on the persistent post-transcriptional elevation in TH mRNA. Thus, the results support the conclusion that VIP and PACAP38 each stimulate PAC1 receptors to increase TH gene transcription through a PKA-controlled pathway, but their divergent post-transcriptional effects result at least partly from differing abilities to stimulate PKC.

Study Information

Provider

pubmed

Year

2002

Date

2002-02-01T00:00:00.000Z

DOI

10.1054/npep.2002.0885

Citations

32

References

57